Evidence map›Paper›PMID 28077643›Full record

ArticleJournal of virology2017

Efficient Vpu-Mediated Tetherin Antagonism by an HIV-1 Group O Strain.

Katharina Mack, Kathrin Starz, Daniel Sauter, Simon Langer, Frederic Bibollet-Ruche, Gerald H Learn, Christina M Stürzel, Marie Leoz, Jean-Christophe Plantier, Matthias Geyer and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.3field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 3 countries.

Katharina MackInstitute of Molecular Virology, Ulm University Medical Center, Ulm, Germany.
Kathrin StarzInstitute of Molecular Virology, Ulm University Medical Center, Ulm, Germany.
Daniel SauterInstitute of Molecular Virology, Ulm University Medical Center, Ulm, Germany.
Simon LangerInstitute of Molecular Virology, Ulm University Medical Center, Ulm, Germany.
Frederic Bibollet-RucheDepartment of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Gerald H LearnDepartment of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Christina M StürzelInstitute of Molecular Virology, Ulm University Medical Center, Ulm, Germany.
Marie LeozLaboratoire de Virologie, CHU Charles Nicolle, Rouen, France.
Jean-Christophe PlantierLaboratoire de Virologie, CHU Charles Nicolle, Rouen, France.
Matthias GeyerDepartment of Structural Immunology, Institute of Innate Immunity, University of Bonn, Bonn, Germany.
Beatrice H HahnDepartment of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Frank KirchhoffInstitute of Molecular Virology, Ulm University Medical Center, Ulm, Germany frank.kirchhoff@uni-ulm.de.
Universität Ulm · DEUniversity of Pennsylvania · USHôpital Charles-Nicolle · FRUniversité de Rouen Normandie · FRUniversity of Bonn · DE

Funding

Virus biology scientific research support componentUM1AI100645 · NIAID · DUKE UNIVERSITY · PI HAYNES, BARTON F. · 2012 to 2018
$204.7M
Virus & Reservoirs CoreP30AI045008 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI ROBERT GROSS · 1999 to 2026
$78.6M
Natural SIV Reservoirs and Human Zoonotic RiskR37AI050529 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI HAHN, BEATRICE H · 2008 to 2017
$5.7M
Studies of the precursor of the human AIDS virus in its natural chimpanzee hostR01AI120810 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI HAHN, BEATRICE H · 2016 to 2020
$3.4M
Restriction of HIV-1 transmission by type 1 interferonsR01AI114266 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI HAHN, BEATRICE H · 2014 to 2018
$3.2M
Harnessing type 1 IFN-stimulated antiviral mechanisms for HIV vaccine designR01AI111789 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI HAHN, BEATRICE H · 2014 to 2017
$816k
NIAID NIH HHS P30 AI045008NIAID NIH HHS R01 AI111789NIAID NIH HHS R01 AI114266NIAID NIH HHS R01 AI120810NIAID NIH HHS R37 AI050529NIAID NIH HHS UM1 AI100645
6 · The paper itself

Abstract

Simian immunodeficiency viruses (SIVs) use their Nef proteins to counteract the restriction factor tetherin. However, a deletion in human tetherin prevents antagonism by the Nef proteins of SIVcpz and SIVgor, which represent the ape precursors of human immunodeficiency virus type 1 (HIV-1). To promote virus release from infected cells, pandemic HIV-1 group M strains evolved Vpu as a tetherin antagonist, while the Nef protein of less widespread HIV-1 group O strains acquired the ability to target a region adjacent to this deletion. In this study, we identified an unusual HIV-1 group O strain (RBF206) that evolved Vpu as an effective antagonist of human tetherin. While both RBF206 Vpu and Nef exert anti-tetherin activity in transient-transfection assays, mainly Vpu promotes RBF206 release in infected CD4

Indexed as

Host-Pathogen InteractionsVirus ReleaseAntigens, CDBone Marrow Stromal Antigen 2CD4-Positive T-LymphocytesCell LineGPI-Linked ProteinsHIV-1Human Immunodeficiency Virus ProteinsHumansNF-kappa BViral Regulatory and Accessory ProteinsViroporin ProteinsAntigens, CDBone Marrow Stromal Antigen 2BST2 protein, humanGPI-Linked ProteinsHuman Immunodeficiency Virus ProteinsNF-kappa BViral Regulatory and Accessory ProteinsViroporin Proteinsvpu protein, Human immunodeficiency virus 1antagonismHIV-1 group OtetherinVpu

Identifiers

PMID28077643
PMCPMC5331793
OpenAlexW2578438214

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.